173 related articles for article (PubMed ID: 38099524)
1. Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer.
Gao Y; Li Y; Zhu Y; Luo Q; Lu Y; Wen K; Du B; Xi X; Li G
Curr Cancer Drug Targets; 2024; 24(5):510-518. PubMed ID: 38099524
[TBL] [Abstract][Full Text] [Related]
2. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G
Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
[TBL] [Abstract][Full Text] [Related]
4. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
5. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
[TBL] [Abstract][Full Text] [Related]
6. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
7. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2.
Khan H; Jia W; Yu Z; Zaib T; Feng J; Jiang Y; Song H; Bai Y; Yang B; Feng H
Biomed Pharmacother; 2020 Aug; 128():110244. PubMed ID: 32464306
[TBL] [Abstract][Full Text] [Related]
8. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
10. FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells.
Lin B; Chen T; Zhang Q; Lu X; Zheng Z; Ding J; Liu J; Yang Z; Geng L; Wu L; Zhou L; Zheng S
Oncotarget; 2016 Nov; 7(47):77495-77507. PubMed ID: 27769048
[TBL] [Abstract][Full Text] [Related]
11. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
[TBL] [Abstract][Full Text] [Related]
12. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.
Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G
Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105
[TBL] [Abstract][Full Text] [Related]
13. Chitosan promotes cancer progression and stem cell properties in association with Wnt signaling in colon and hepatocellular carcinoma cells.
Chang PH; Sekine K; Chao HM; Hsu SH; Chern E
Sci Rep; 2017 Apr; 8():45751. PubMed ID: 28367998
[TBL] [Abstract][Full Text] [Related]
14. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
15. Microporous cellulosic scaffold as a spheroid culture system modulates chemotherapeutic responses and stemness in hepatocellular carcinoma.
Wu G; Zhan S; Rui C; Sho E; Shi X; Ding Y
J Cell Biochem; 2019 Apr; 120(4):5244-5255. PubMed ID: 30302811
[TBL] [Abstract][Full Text] [Related]
16. Tunicamycin inhibits cell proliferation and migration in hepatocellular carcinoma through suppression of CD44s and the ERK1/2 pathway.
Hou H; Ge C; Sun H; Li H; Li J; Tian H
Cancer Sci; 2018 Apr; 109(4):1088-1100. PubMed ID: 29377347
[TBL] [Abstract][Full Text] [Related]
17. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma.
Modi SJ; Kulkarni VM
Eur J Med Chem; 2020 Dec; 207():112851. PubMed ID: 33002846
[TBL] [Abstract][Full Text] [Related]
18. Effect of emodin combined with cisplatin on the invasion and migration of HepG2 hepatoma cells.
Yang M; Xiong Z; Deng H; Chen X; Lai Q; Wang H; Leng Y
J Physiol Pharmacol; 2023 Aug; 74(4):. PubMed ID: 37865957
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-β-induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma.
Malfettone A; Soukupova J; Bertran E; Crosas-Molist E; Lastra R; Fernando J; Koudelkova P; Rani B; Fabra Á; Serrano T; Ramos E; Mikulits W; Giannelli G; Fabregat I
Cancer Lett; 2017 Apr; 392():39-50. PubMed ID: 28161507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]